Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1760

Sort by

Sort Order Select

Journal Articles

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Shyamala C. Navada, MD, Guillermo Garcia-Manero, MD, Ehab L. Atallah, MD, M. Nabeel Rajeh, MD, Jamile M. Shammo, MD, Elizabeth A. Griffiths, MD, Samer K. Khaled, MD, Shaker R. Dakhil, MD, David E. Young, MD, Rosalie Odchimar-Reissig, RN, Afoluso Ronnee Adesanya, MD, Patrick S. Zbyszewski, MBA, Richard C. Woodman, MD, Pierre Fenaux, MD PhD, Lewis R. Silverman, MD

Blood (2019) 134 (Supplement_1): 566.

https://doi.org/10.1182/blood-2019-131676

Published: 2019

Journal Articles

Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB)

Meera Yogarajah, MD, Phuong L. Nguyen, MD, Rong He, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, Mrinal M Patnaik, MDMBBS, Kebede H. Begna, MD, Michelle A Elliott, MD, Naseema Gangat, MBBS, William J Hogan, MB, BCh, Ayalew Tefferi, MD, Mark Litzow, MD, Aref Al-Kali, MD

Blood (2019) 134 (Supplement_1): 5441.

https://doi.org/10.1182/blood-2019-125439

Published: 2019

Journal Articles

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

Daniele Avenoso, MD, Margherita Squillario, Annalisa Barla, Alessandro Verri, Enrico Carminati, Clara Nurra, Elisabetta Todisco, MD PhD, Federica Gigli, MD, Giuliana Gregato, Claudia Poletti, Francesco Bertolini, MD PhD, Ghulam J. Mufti, MBBS, FRCP, FRCPath, DM, Mili Shah, FRCPath, Maurizio Miglino

Blood (2019) 134 (Supplement_1): 5414.

https://doi.org/10.1182/blood-2019-130153

Published: 2019

Journal Articles

Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS

Blood (2019) 134 (Supplement_1): 5416.

https://doi.org/10.1182/blood-2019-129464

Published: 2019

Journal Articles

Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacyitidine: A Retrospective Analysis from the Hellenic MDS Study Group

Elena E. Solomou, MD, Alexandra Kourakli, MD PhD, Anna Vardi, MD PhD, Ioannis Kotsianidis, MD PhD, Panagiotis Zikos, MD, Vassiliki Pappa, MD, Athanasios Galanopoulos, MD PhD, Aikaterini Palla, Athina Vyniou, Charalampos Pontikoglou, MD PhD, Panagiotis T Diamantopoulos, MD PhD, Theodoros Vassilakopoulos, MD, Aikaterini Megalakaki, Eleni Variami, Helen A. Papadaki, MD PhD, George Vassilopoulos, MD PhD, Achilles Anagnostopoulos, Argiris Symeonidis, MD PhD

Blood (2019) 134 (Supplement_1): 5417.

https://doi.org/10.1182/blood-2019-131003

Published: 2019

Journal Articles

Plasmacytoid Dendritic Cell Proportion Is Predictive of Risk and Outcomes in Myelodysplastic Syndromes

Alexander Chan, MD, Yanming Zhang, MD, Sean M. Devlin, PhD, Natasha Lewis, MD, Jeeyeon Baik, Maria E Arcila, MD, Virginia M. Klimek, MD, Mikhail Roshal, MD PhD, Wenbin Xiao, MD PhD

Blood (2019) 134 (Supplement_1): 5439.

https://doi.org/10.1182/blood-2019-122332

Published: 2019

Journal Articles

Patient-Specific Risk Factors Independently Influence Survival in Myelodysplastic Syndromes in an Unbiased Review of EHR Records

Travis Spaulding, MD, Nicholas Strayer, Andrew Sochacki, MD, Shannon Stockton, MD, Alexander Silver, Rodney Dixon Dorand, MD PhD, Siwei Zhang, PhD, Ya-Chen Lin, Yaomin Xu, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 5440.

https://doi.org/10.1182/blood-2019-122400

Published: 2019

Journal Articles

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Kelly S. Chien, MD, Gautam M. Borthakur, MD, Kiran Naqvi, MDMPH, Naval G. Daver, MD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Elias Jabbour, MD, Michael Andreeff, MD PhD, Yesid Alvarado, MD, Prithviraj Bose, MD, Nitin Jain, MD, Kimberly Sheppard, BSN, RN, Cheri Klingner-Winton, Sherry A. Pierce, BSN, BA, Xiao Qin Dong, Kelly Soltysiak, PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 4240.

https://doi.org/10.1182/blood-2019-129598

Published: 2019

Journal Articles

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

Brian J Ball, Christopher Famulare, MS, Eytan M. Stein, MD, Martin S. Tallman, MD, Saar I. Gill, MD PhD, Benjamin M Manning, MD PhD, Jamie Koprivnikar, MD, James McCloskey, MD, Rebecca Testi, NP-C, BSN, RN, MSN, OCN, Najla Al Ali, M.Sc, David A Sallman, MD, Eric Padron, MD, Aaron D Goldberg, MD PhD, Rami S. Komrokji, MD

Blood (2019) 134 (Supplement_1): 4241.

https://doi.org/10.1182/blood-2019-125113

Published: 2019

Journal Articles

The Scenario of Myelofibrosis in Brazil in the View of a Panel of Experts: Challenges and Proposals

Laura Maria Fogliatto, MD PhD, Cristiana Solza, MD PhD, Alexandre Gustavo Apa, MD, Gustavo HR Magalhaes, MD MSc, Marcia Torresan Delamain, MD, Renato Tavares, MD, Lorena Lobo Figueiredo-Pontes, MD PhD

Blood (2019) 134 (Supplement_1): 5851.

https://doi.org/10.1182/blood-2019-121960

Published: 2019

Journal Articles

A Systematic Literature Review on the Burden of Illness in Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes

Sohan Deshpande, Monica Turner, Michael Byrnes, Christopher Pelligra, Amy Rines-MacEachern, Madhura Chitnis, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Derek Tang, PhD BSPharm, Jessica Morison, Esther Natalie Oliva, MD

Blood (2019) 134 (Supplement_1): 5838.

https://doi.org/10.1182/blood-2019-124300

Published: 2019

Journal Articles

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Barry S. Skikne, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Tara L. Lin, MD, Leyla Shune, MD, Neil Dunavin, MD, Ajoy L. Dias, MD, Brian McClune, DO, Abdulraheem Yacoub, MD, Clint Divine, Haitham Abdelhakim, MD, Siddhartha Ganguly, MD, Jennifer Hanses, Carol E Webb, BA, Joseph P. McGuirk, DO

Blood (2019) 134 (Supplement_1): 5743.

https://doi.org/10.1182/blood-2019-130828

Published: 2019

Journal Articles

Cord Blood Transplantation Is an Effective Treatment Option in Patients with Myelodysplastic and Myeloproliferative Syndromes

Laura Roberts, Rachel B. Salit, MD, Lauren Longo, Elisabetta Xue, MD, Corinne Summers, MD, Colleen Delaney, MD MSc, Ann Dahlberg, MD, Filippo Milano, MD PhD

Blood (2019) 134 (Supplement_1): 2048.

https://doi.org/10.1182/blood-2019-126216

Published: 2019

Journal Articles

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Sabine Khalife-Hachem, Khalil Saleh, MD, Florence Pasquier, MD PhD, Anthony Tarabay, Cyril Quivoron, Sophie Cotteret, Christophe Willekens, MD, Veronique Saada, Ines-Maria Vaz-Luis, Suzette Delaloge, Alexandra Leary, Hana Raslova, PhD, Filippo Rosselli, Olivier Caron, Iléana Antony-Debre, PhD, Eric Solary, MD PhD, Stephane de Botton, MD PhD, Christophe Marzac, MD, Jean-Baptiste Micol, MD

Blood (2019) 134 (Supplement_1): 3722.

https://doi.org/10.1182/blood-2019-126872

Published: 2019

Journal Articles

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

Blood (2019) 134 (Supplement_1): 3821.

https://doi.org/10.1182/blood-2019-128153

Published: 2019

Journal Articles

IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series

Irene Dogliotti, MD, Cristina Jiménez, PhD, Federica Cavallo, MD PhD, Noemi Puig, MD PhD, Gian Maria Zaccaria, PhD, Veronica Gonzalez De La Calle, MD PhD, Maria Eugenia Sarasquete, PhD, Miguel Alcoceba, Pilar Delgado, MD, Maria Rosa López, MD, Aránzazu García Mateo, PhD, Simone Ferrero, MD, Mario Boccadoro, Marcos González, Ramón García-Sanz, MD PhD

Blood (2019) 134 (Supplement_1): 4011.

https://doi.org/10.1182/blood-2019-123353

Published: 2019

Journal Articles

Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

Thierry Guillaume, MD PhD, Pierre Peterlin, Sylvain Thepot, MD, Amandine Le Bourgeois, MD, Alice Garnier, MD, Sylvie François, MD, Corentin Orvain, Yannick Le Bris, PharmD, Clémentine Fronteau, PharmD, Patrice Chevallier, MD

Blood (2019) 134 (Supplement_1): 4555.

https://doi.org/10.1182/blood-2019-123402

Published: 2019

Journal Articles

De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes

Zachary D. Epstein-Peterson, MD, Barbara Spitzer, MD, Joseph McCarter, PhD, Erin McGovern, BA, Ross L. Levine, MD, Martin S. Tallman, MD

Blood (2019) 134 (Supplement_1): 2708.

https://doi.org/10.1182/blood-2019-123400

Published: 2019

Journal Articles

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Montserrat Arnan Sangerman, Helena Pomares, MD PhD, Esther Alonso, MD, Javier Grau, MD PhD, Mercedes Galiano, Maite Encuentra, Anna Sureda, MD PhD

Blood (2019) 134 (Supplement_1): 3013.

https://doi.org/10.1182/blood-2019-127486

Published: 2019

Journal Articles

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Guillermo Garcia-Manero, MD, Anna Jonasova, MD PhD, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, David Valcárcel, MD, Erica D. Warlick, MD, Wieslaw W. Jedrzejczak, MD PhD, María Díez-Campelo, MD PhD, Patrick S. Zbyszewski, MBA, Christopher Cavanaugh, Richard C. Woodman, MD, Steven M. Fruchtman, MD, Koichi Takahashi, MD

Blood (2019) 134 (Supplement_1): 3015.

https://doi.org/10.1182/blood-2019-131632

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase II Study of Oral Rigosertib Combined with Azacitidine (AZA) As First Line Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS)

Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB)

Next Generation Sequencing and Microrna Assay in a Cohort of Patients Affected By Myelodysplastic Syndromes. an Analysis of Clinical and Genotypic Features

Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS

Prognostic Significance of Bone Marrow Cellularity in the Outcome of Patients with Myelodysplastic Syndromes Treated with Azacyitidine: A Retrospective Analysis from the Hellenic MDS Study Group

Plasmacytoid Dendritic Cell Proportion Is Predictive of Risk and Outcomes in Myelodysplastic Syndromes

Patient-Specific Risk Factors Independently Influence Survival in Myelodysplastic Syndromes in an Unbiased Review of EHR Records

Updated Preliminary Results from a Phase II Study Combining Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome

Combined Venetoclax and Hypomethylating Agent (HMA) Therapy Induces High Response Rates in Patients with Myelodysplastic Syndrome Including Patients Previously Failing HMA

The Scenario of Myelofibrosis in Brazil in the View of a Panel of Experts: Challenges and Proposals

A Systematic Literature Review on the Burden of Illness in Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Cord Blood Transplantation Is an Effective Treatment Option in Patients with Myelodysplastic and Myeloproliferative Syndromes

Clonal Hematopoiesis in the Molecular Landscape of Therapy-Related Myeloid Neoplasms in Patients Previously Treated for Gynecologic and Breast Cancers

Expanding on Current Definitions of Hematologic Improvement in MDS, CMML and AML: Landmark Analyses of 1301 Patients Treated with Azacitidine in the Austrian Registry of Hypomethylating Agents By the AGMT-Study Group

IgM-Gammopathies Transformed into Aggressive Lymphoma: Incidence, Basal Clinical Features and Outcome of a Registry Based, Spanish Retrospective Series

Prophylactic or Preemptive Low-Dose Azacitidine (AZA) and Donor Lymphocyte Infusion (DLI) Prevent Disease Relapse Following Allogeneic Transplantation in High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome

De Novo Myelodysplastic Syndromes in Patients 20-50 Years Old Characterized By Frequent Mutations in TP53 and Transcription-Related Genes

Impact of Red Blood Cell Transfusion Burden Status in Patients with Lower-Risk Myelodysplastic Syndromes

Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only